Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 4, 2008, Pages 343-346

  Roch, Nathalie ^a   Salameire, Dimitri ^a   Gressin, Remy ^a   Morand, Patrice ^a   Epaulard, Olivier ^a   Pavese, Patricia ^a   Brion, Jean Paul ^a   Stahl, Jean Paul ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; GANCICLOVIR; RITUXIMAB;

ADENOVIRUS; AGED; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG FATALITY; ENTEROVIRUS INFECTION; EPSTEIN BARR VIRUS; HUMAN; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; OPPORTUNISTIC INFECTION; SEZARY SYNDROME; VIRUS INFECTION;

ADENOVIRUS INFECTIONS, HUMAN; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ENTEROVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; MALE; OPPORTUNISTIC INFECTIONS; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 41349110656     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701684817     Document Type: Article

References (12)

1. Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S. and Juliusson, G. (2003) Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood, 101, pp. 4267-4272.
2. Thursky, KA, Worth, LJ, Seymour, JF, Prince, H Miles and Slavin, MA. (2006) Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol, 132, pp. 3-12.
3. Martin, SI, Marty, FM, Fiumara, K., Treon, SP, Gribben, JG and Baden, LR. (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis, 43, pp. 16-24.
4. Karlsson, C., Norin, S., Kimby, E., Sander, B., Macdonald, A Porwit and Nilsson, B. (2006) Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukaemia: Long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia, 20, pp. 2204-2207.
5. Fiegl, M., Falkner, A., Hopfinger, G., Brugger, S., Zabernigg, A. and Bauer, F. (2006) Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukaemia: A nation-wide retrospective study in Austria. Cancer, 107, pp. 2408-2416.
6. Peleg, AY, Husain, S., Kwak, EJ, Silveira, FP, Ndirangu, M. and Tran, J. (2007) Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD52 antibody. Clin Infect Dis, 44, pp. 204-212.
7. Ghobrial, IM, Otteman, LA and White, WL. (2003) An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med, 349, pp. 2570-2572.
8. O'Brien, SM, Kantarjian, HM, Thomas, DA, Cortes, J., Giles, FJ and Wierda, WG (2003) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukaemia. Cancer, 98, pp. 2657-2663.
9. O'Brien, SM, Keating, MJ and Mocarski, ES. (2006) Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukaemia treated with alemtuzumab. Clin Lymphoma Myeloma, 7, pp. 125-130.
10. Janssens, A., Berth, M., De Paepe, P., Verhasselt, B., Van Roy, N. and Noens, L. (2006) EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient. Am J Hematol, 81, pp. 706-712.
11. Cavalli-Bjorkman, N., Osby, E., Lundin, J., Kalin, M., Osterborg, A. and Gruber, A. (2002) Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukaemia. Med Oncol, 19, pp. 277-280.
12. Myers, GD, Krance, RA, Weiss, H., Kuehnle, I., Demmler, G. and Heslop, HE (2005) Adenovirus infection rates in paediatric recipients of alternate donor allogeneic bone marrow transplants receiving either anti-thymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant, 36, pp. 1001-1008.